JP2019509014A - Ｃｄ３９血管アイソフォームターゲティング剤 - Google Patents

Ｃｄ３９血管アイソフォームターゲティング剤 Download PDF

Info

Publication number
JP2019509014A
JP2019509014A JP2018526708A JP2018526708A JP2019509014A JP 2019509014 A JP2019509014 A JP 2019509014A JP 2018526708 A JP2018526708 A JP 2018526708A JP 2018526708 A JP2018526708 A JP 2018526708A JP 2019509014 A JP2019509014 A JP 2019509014A
Authority
JP
Japan
Prior art keywords
optionally
antibody
amino acid
residue
kabat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018526708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509014A5 (enExample
Inventor
ジェレミー・バスティド
ローラン・ゴーティエ
カリーヌ・パトゥレル
イヴァン・ペロ
アラン・ルセル
ベアトリス・アミグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of JP2019509014A publication Critical patent/JP2019509014A/ja
Publication of JP2019509014A5 publication Critical patent/JP2019509014A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
JP2018526708A 2015-11-23 2016-11-22 Ｃｄ３９血管アイソフォームターゲティング剤 Pending JP2019509014A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201562258701P 2015-11-23 2015-11-23
US62/258,701 2015-11-23
US201562263760P 2015-12-07 2015-12-07
US62/263,760 2015-12-07
US201562267343P 2015-12-15 2015-12-15
US62/267,343 2015-12-15
US201662320738P 2016-04-11 2016-04-11
US62/320,738 2016-04-11
US201662404779P 2016-10-06 2016-10-06
US62/404,779 2016-10-06
PCT/EP2016/078395 WO2017089334A1 (en) 2015-11-23 2016-11-22 Cd39 vascular isoform targeting agents

Publications (2)

Publication Number Publication Date
JP2019509014A true JP2019509014A (ja) 2019-04-04
JP2019509014A5 JP2019509014A5 (enExample) 2019-12-12

Family

ID=57391960

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018526708A Pending JP2019509014A (ja) 2015-11-23 2016-11-22 Ｃｄ３９血管アイソフォームターゲティング剤

Country Status (6)

Country Link
US (1) US20190153113A1 (enExample)
EP (1) EP3380519A1 (enExample)
JP (1) JP2019509014A (enExample)
AU (1) AU2016359790A1 (enExample)
CA (1) CA3005986A1 (enExample)
WO (1) WO2017089334A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545585A (ja) * 2019-08-27 2022-10-28 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
JP2025508956A (ja) * 2022-03-03 2025-04-10 アーカス バイオサイエンシズ インコーポレイティド 抗ｃｄ３９抗体及びその使用

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2238170T (pt) 2008-01-31 2017-02-21 Inserm - Inst Nat De La Santé Et De La Rech Médicale Anticorpos contra cd39 humano e seu uso para inibição da actividade de células t reguladoras
JP7461741B2 (ja) 2016-06-20 2024-04-04 カイマブ・リミテッド 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
WO2018209324A2 (en) 2017-05-11 2018-11-15 The Broad Institute, Inc. Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
JP7113071B2 (ja) * 2017-07-31 2022-08-04 トリシュラ セラピューティクス， インコーポレイテッド 抗ｃｄ３９抗体、抗ｃｄ３９抗体を含む組成物、および抗ｃｄ３９抗体を使用する方法
SG11202002192QA (en) * 2017-10-06 2020-04-29 Innate Pharma Restoration of t cell activity via the cd39/cd73 axis
CN111372606B (zh) * 2017-11-15 2024-02-20 先天制药公司 增强atp释放作用
CN120617499A (zh) 2018-01-10 2025-09-12 生物发明国际公司 抗体的新型组合和用途
MX2020011588A (es) 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
TWI869346B (zh) * 2018-05-30 2025-01-11 瑞士商諾華公司 Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
US20210253731A1 (en) * 2018-06-14 2021-08-19 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis
TWI870353B (zh) * 2018-06-18 2025-01-21 法商天賜製藥公司 用於治療癌症之組合物及方法
CN113727999A (zh) 2019-01-11 2021-11-30 奥默罗斯公司 用于治疗癌症的方法和组合物
AU2020239048B2 (en) 2019-03-12 2025-10-16 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
JP7743309B2 (ja) 2019-03-29 2025-09-24 アーカス バイオサイエンシズ インコーポレイティド 同定されたアデノシンフィンガープリントを利用したがんの処置
AU2020328507A1 (en) 2019-08-12 2022-03-17 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating T-cell mediated immune responses through ADCC targeting of CD39 expressing cells
US11655303B2 (en) 2019-09-16 2023-05-23 Surface Oncology, Inc. Anti-CD39 antibody compositions and methods
CN110407941B (zh) * 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
TW202118791A (zh) 2019-11-05 2021-05-16 大陸商北京加科思新藥研發有限公司 對cd39具有特異性的結合分子及其用途
US20230036592A1 (en) * 2021-06-03 2023-02-02 Surface Oncology, Inc. Methods of treating cancer with an anti-cd39 antibody and pembrolizumab
TW202400647A (zh) 2022-04-29 2024-01-01 美商普瑞諾生物科技公司 用於治療嗜酸性球驅動之疾病及病症的方法及組成物
WO2024115935A1 (en) * 2022-11-29 2024-06-06 Inserm Methods for the treatment of b-cell lymphoma using cd39 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) * 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
WO2012085132A1 (en) * 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
JP2014523408A (ja) * 2011-06-06 2014-09-11 ノヴォ ノルディスク アー／エス 治療抗体

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011510953A (ja) * 2008-01-31 2011-04-07 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 制御性ｔ細胞活性を抑制するための、ヒトｃｄ３９に対する抗体およびその使用
WO2012085132A1 (en) * 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
JP2014523408A (ja) * 2011-06-06 2014-09-11 ノヴォ ノルディスク アー／エス 治療抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MALISZEWSKI CR. ET AL.: "The CD39 lymphoid cell activation antigen. Molecular cloning and structural characterization", THE JOURNAL OF IMMUNOLOGY, vol. 153(8), JPN6020035462, 1994, pages 3574 - 3583, ISSN: 0004564635 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022545585A (ja) * 2019-08-27 2022-10-28 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
US12312410B2 (en) 2019-08-27 2025-05-27 Elpiscience (Suzhou) Biopharma, Ltd Anti-CD39 antibodies
JP7727387B2 (ja) 2019-08-27 2025-08-21 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
JP2025508956A (ja) * 2022-03-03 2025-04-10 アーカス バイオサイエンシズ インコーポレイティド 抗ｃｄ３９抗体及びその使用
JP7712496B2 (ja) 2022-03-03 2025-07-23 アーカス バイオサイエンシズ インコーポレイティド 抗ｃｄ３９抗体及びその使用

Also Published As

Publication number Publication date
WO2017089334A1 (en) 2017-06-01
AU2016359790A1 (en) 2018-06-21
US20190153113A1 (en) 2019-05-23
CA3005986A1 (en) 2017-06-01
EP3380519A1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
JP7132981B2 (ja) Ｃｄ７３遮断
US20230340143A1 (en) Compositions and methods for treating cancer
JP2019509014A (ja) Ｃｄ３９血管アイソフォームターゲティング剤
US20220056145A1 (en) Anti-cd39 antibodies
KR102826033B1 (ko) 암을 치료하기 위한 조성물 및 방법
EP3377529B1 (en) Siglec-10 antibodies
RU2781116C1 (ru) Составы и способы для лечения рака
HK40040395B (zh) 用於治疗癌症的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200923

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220215